"""
Question: 1101

Evidence: Between 2016 and 2019, blood samples were received from 258 patients with HIV-1 infection. From January 2016 to December 2019, a total number of 258 blood samples were received for routine HIV-1 drug resistance testing.

Rationale: The paper describes a study conducted between 2016 and 2019, analyzing blood samples from 258 patients. This indicates the data being reported is from the authors' own research and data collection during this period, which constitutes previously unpublished data.

Answer: Yes
"""

"""
Question: 1102

Evidence: Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16–48 weeks of treatment with integrase strand transfer inhibitor-based regimen. Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene, as described previously.

Rationale: The paper explicitly states that the HIV-1 pol gene sequences were determined, and that specific regions (protease/reverse transcriptase and integrase) were amplified and sequenced. This confirms the reporting of HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: The research study was carried out in accordance with the recommendations of the Ethical Decision Committee of the Research Administration, Faculty of Medicine, Kuwait University, and the 2008 Declaration of Helsinki. Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks.

Rationale: The paper describes a clinical study involving patient follow-up and sample collection from treated individuals. There is no mention of any in vitro passage experiments, which involve growing the virus in cell culture under drug pressure. The methods are entirely based on clinical sampling.

Answer: No
"""

"""
Question: 1104

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper describes the use of genotypic resistance testing (sequencing and interpretation algorithms) to predict resistance. It does not mention performing any in vitro experiments to measure the actual susceptibility of the virus to antiretroviral drugs (phenotypic testing).

Answer: No
"""

"""
Question: 2101

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper describes the methods for sequence analysis but does not mention submitting the sequences to GenBank or reporting any GenBank accession numbers.

Answer: No
"""

"""
Question: 2102

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper does not report any GenBank accession numbers for any HIV isolates, whether from the study or from laboratory strains.

Answer: No
"""

"""
Question: 2103

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper does not mention or list any GenBank accession numbers.

Answer: NA
"""

"""
Question: 2202

Evidence: Table 2 shows the specific mutations (e.g., K101E, Y181C, G190S, M184V, Y143C, N155H) found in each individual patient (Patients 1-7). M184V mutation associated with high level resistance to lamivudine and emtricitabine was detected in six out of seven patients.

Rationale: Table 2 is explicitly titled "Mutations associated with resistance... in patients with virologic failure" and lists the specific resistance mutations (NRTI, NNRTI, InSTI) detected for each of the seven patients, providing individual-level mutation data.

Answer: Yes
"""

"""
Question: 2301

Evidence: Blood samples were received from 258 patients with HIV-1 infection. All patients were Kuwaiti including two females and five males.

Rationale: The paper exclusively studies patients infected with HIV-1, as stated in the abstract and throughout the text. There is no mention of HIV-2 or other HIV species.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: One patient was infected with HIV-1 subtype C, and the rest with subtype CRF01_AE. All patients with virologic failure but one were infected with CRF01_AE virus subtype.

Rationale: The results section explicitly states the subtypes of the viruses from the seven patients with virologic failure: one was subtype C and six were CRF01_AE.

Answer: CRF01_AE, C
"""

"""
Question: 2303

Evidence: Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene. The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The methods section clearly states that two regions of the HIV-1 pol gene were sequenced: the protease/reverse transcriptase region and the integrase region.

Answer: protease, reverse transcriptase, integrase
"""

"""
Question: 2304

Evidence: Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene. The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper explicitly states that the HIV-1 pol gene was sequenced, covering the protease, reverse transcriptase, and integrase regions.

Answer: Yes
"""

"""
Question: 2401

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. There were all recruited from Infectious Disease Hospital, Ministry of Health, Kuwait. All patients were Kuwaiti including two females and five males.

Rationale: The study population was recruited from a hospital in Kuwait, and all patients with virologic failure were Kuwaiti. This indicates the sequences are from Kuwait.

Answer: Kuwait
"""

"""
Question: 2402

Evidence: The study period was from January 2016 to December 2019. Between 2016 and 2019, blood samples were received from 258 patients with HIV-1 infection.

Rationale: The paper clearly states that the study period and sample collection occurred between January 2016 and December 2019.

Answer: 2016-2019
"""

"""
Question: 2502

Evidence: The ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA) was used to determine the nucleotide sequences of 5' and 3' DNA strands as described previously. The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The use of an ABI 3500 Genetic Analyzer for sequencing is indicative of Sanger sequencing technology. The mention of bulk sequencing and its limitation (detecting variants >20%) further confirms this.

Answer: Yes
"""

"""
Question: 2503

Evidence: This may result from a combination of different factors that have been clearly explained elsewhere.8 One of these factors is the presence of drug resistant minority viral populations that failed to be detected by a standard sequencing method as described above, and required more sensitive method like next generation sequencing.

Rationale: The paper explicitly states that the standard sequencing method used was not Next Generation Sequencing (NGS), and that NGS would be a more sensitive alternative. This confirms that NGS was not used in this study.

Answer: No
"""

"""
Question: 2504

Evidence: The MagNa Pure LC 2.0 system (Roche Diagnostic Systems) was used to isolate total RNA from plasma samples. Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene.

Rationale: The described methodology involves RNA extraction and PCR amplification, but there is no mention of cloning the PCR products prior to sequencing.

Answer: No
"""

"""
Question: 2505

Evidence: The MagNa Pure LC 2.0 system (Roche Diagnostic Systems) was used to isolate total RNA from plasma samples. Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene.

Rationale: The paper describes standard bulk PCR amplification and sequencing. There is no mention of single genome sequencing (SGS), a technique that specifically limits PCR amplification to a single template molecule.

Answer: No
"""

"""
Question: 2506

Evidence: The MagNa Pure LC 2.0 system (Roche Diagnostic Systems) was used to isolate total RNA from plasma samples. Two nested reverse transcription polymerase chain reactions (RT-PCR) were performed to amplify the protease/reverse transcriptase region, and the integrase region in the HIV-1 pol gene.

Rationale: The methodology describes PCR amplification but does not mention inserting the amplicons into a vector for molecular cloning before sequencing.

Answer: No
"""

"""
Question: 2601

Evidence: The MagNa Pure LC 2.0 system (Roche Diagnostic Systems) was used to isolate total RNA from plasma samples. HIV-1 RNA concentrations in the plasma samples of patients were measured within 16--48 weeks of treatment.

Rationale: The paper explicitly states that sequencing was performed on RNA isolated from plasma samples, indicating plasma virus sequencing.

Answer: Yes
"""

"""
Question: 2602

Evidence: The MagNa Pure LC 2.0 system (Roche Diagnostic Systems) was used to isolate total RNA from plasma samples.

Rationale: The paper only describes the isolation of RNA from plasma samples for sequencing. It does not mention sequencing from PBMCs (Peripheral Blood Mononuclear Cells) or isolating DNA from PBMCs.

Answer: No
"""

"""
Question: 2603

Evidence: From January 2016 to December 2019, a total number of 258 blood samples were received for routine HIV-1 drug resistance testing. The samples were collected from 191 patients newly diagnosed with HIV-1 infection, and 67 ART-experienced patients.

Rationale: The study received 258 blood samples for resistance testing, and the methodology states that RNA was isolated from plasma for sequencing from these samples. Therefore, 258 samples underwent plasma virus sequencing.

Answer: 258
"""

"""
Question: 2604

Evidence: The MagNa Pure LC 2.0 system (Roche Diagnostic Systems) was used to isolate total RNA from plasma samples.

Rationale: The paper only describes sequencing from plasma RNA. There is no mention of sequencing from PBMC DNA or any other cell-associated source.

Answer: 0
"""

"""
Question: 2605

Evidence: Only patients who did not achieve viral suppression at 48 weeks of integrase strand transfer inhibitor-based treatment were eligible for the current study. Virologic failure is defined as viral load above 200 copies/mL on at least two consecutive measurements.

Rationale: The study specifically focused on patients with virologic failure, which is defined as a detectable viral load (>200 copies/mL), indicating active HIV replication.

Answer: Yes
"""

"""
Question: 2606

Evidence: The MagNa Pure LC 2.0 system (Roche Diagnostic Systems) was used to isolate total RNA from plasma samples.

Rationale: The paper explicitly states that sequencing was performed on RNA isolated from plasma, which represents replicating virus. It does not mention sequencing from proviral DNA, which would require DNA isolation from cells like PBMCs.

Answer: No
"""

"""
Question: 2701

Evidence: Their median age was 40 years (range, 4--45 years). Patient "4" was 7 years old and Patient "7" was 4 years old.

Rationale: The age range of the patients with virologic failure includes children (4 and 7 years old), as shown in Table 1.

Answer: Yes
"""

"""
Question: 2702

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. There were all recruited from Infectious Disease Hospital, Ministry of Health, Kuwait.

Rationale: The study describes patient follow-up in a clinical setting (a hospital). There is no mention of a structured clinical trial; it appears to be an observational study of routine clinical practice.

Answer: No
"""

"""
Question: 2703

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. There were all recruited from Infectious Disease Hospital, Ministry of Health, Kuwait.

Rationale: As there is no indication that any individuals were in a clinical trial, it follows that not all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: From January 2016 to December 2019, a total number of 258 blood samples were received for routine HIV-1 drug resistance testing. The samples were collected from 191 patients newly diagnosed with HIV-1 infection, and 67 ART-experienced patients.

Rationale: The paper states that samples were received from 258 patients in total (191 ART-naive + 67 ART-experienced). These samples were used for HIV sequencing.

Answer: 258
"""

"""
Question: 3102

Evidence: From January 2016 to December 2019, a total number of 258 blood samples were received for routine HIV-1 drug resistance testing.

Rationale: The paper states that 258 samples were received for resistance testing, which includes genotyping (sequencing). This implies that all 258 individuals from whom samples were taken underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: The samples were collected from 191 patients newly diagnosed with HIV-1 infection, and 67 ART-experienced patients.

Rationale: The paper explicitly states that 191 patients were newly diagnosed, which typically implies they are ART-naive.

Answer: Yes
"""

"""
Question: 4102

Evidence: The samples were collected from 191 patients newly diagnosed with HIV-1 infection, and 67 ART-experienced patients.

Rationale: The paper explicitly states that 67 patients were ART-experienced.

Answer: Yes
"""

"""
Question: 4103

Evidence: The samples were collected from 191 patients newly diagnosed with HIV-1 infection, and 67 ART-experienced patients.

Rationale: The paper reports sequences from both ART-naive (191) and ART-experienced (67) individuals.

Answer: Yes
"""

"""
Question: 4104

Evidence: The samples were collected from 191 patients newly diagnosed with HIV-1 infection, and 67 ART-experienced patients.

Rationale: The paper states that 191 patients were newly diagnosed, which typically implies they are ART-naive.

Answer: 191
"""

"""
Question: 4105

Evidence: Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients. Patients "1" through "3" were on NNRTI-based regimen before starting RAL-based regimen as salvage therapy. Patients "4" through "7" who had no previous exposure to ART, failed RAL-based regimen offered as first-line treatment.

Rationale: While the paper provides detailed ART history for the 7 patients with virologic failure, it does not state that complete ART history was available for all 258 individuals in the broader study.

Answer: No
"""

"""
Question: 4201

Evidence: Major non-polymorphic mutations that confer resistance to InSTIs were not detected in 53 InSTI-naı ¨ ve patients.18 Given the scarce information on HIV-1 drug resistance in real clinical settings, especially in the Arabian Gulf region, we aimed in this report to characterize the patterns of mutations detected among patients who did not achieve viral suppression following 48 weeks of treatment with InSTI-based regimen.

Rationale: The paper focuses on characterizing mutations in patients with treatment failure, not on estimating the prevalence of transmitted drug resistance in a population of ART-naive individuals.

Answer: No
"""

"""
Question: 4202

Evidence: Only patients who showed suboptimal viral suppression or virologic failure during InsTI-based therapy were eligible for this study. We aimed in this report to characterize the patterns of mutations detected among patients who did not achieve viral suppression following 48 weeks of treatment with InSTI-based regimen.

Rationale: The study specifically enrolled patients who experienced virologic failure *during* InSTI-based therapy. It does not report on the prevalence of resistance mutations before starting any treatment (pretreatment resistance) in a defined cohort.

Answer: No
"""

"""
Question: 4301

Evidence: The InSTI-based regimen generally consists of one InSTI plus two nucleoside reverse transcriptase inhibitors (NRTIs). Patients "1" through "3" were on NNRTI-based regimen before starting RAL-based regimen as salvage therapy.

Rationale: The paper discusses individuals who received InSTIs, NRTIs, and some who previously received NNRTIs. There is no mention of individuals receiving Protease Inhibitors (PIs).

Answer: Integrase strand transfer inhibitors (InSTIs), Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
"""

"""
Question: 4302

Evidence: Among patients treated with InSTI-based regimen, virologic failure was observed in a total of seven patients on RAL-based regimen, while viral suppression was achieved in all patients on EVG-based regimen (Stribild or Genvoya), or DTG-based regimen (Tivicay + Descovy or Truvada or Epzicom).

Rationale: The paper explicitly reports on patients who received integrase inhibitors (RAL, EVG, DTG).

Answer: Yes
"""

"""
Question: 4303

Evidence: The InSTI-based regimen generally consists of one InSTI plus two nucleoside reverse transcriptase inhibitors (NRTIs).

Rationale: The regimens described in the paper consist of an InSTI plus two NRTIs. There is no mention of any patient receiving a protease inhibitor (PI)-based regimen.

Answer: No
"""

"""
Question: 4304

Evidence: Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients. Among patients treated with InSTI-based regimen, virologic failure was observed in a total of seven patients on RAL-based regimen, while viral suppression was achieved in all patients on EVG-based regimen (Stribild or Genvoya), or DTG-based regimen.

Rationale: The paper shows that patients received different InSTI-based regimens (RAL, EVG, DTG) and different NRTI backbones (e.g., TDF/FTC, ABC/3TC, AZT/3TC). Therefore, not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305

Evidence: Only patients who did not achieve viral suppression at 48"""
Question: 4305

Evidence: Only patients who did not achieve viral suppression at 48 weeks of integrase strand transfer inhibitor-based treatment were eligible for the current study. Among patients treated with InSTI-based regimen, virologic failure was observed in a total of seven patients on RAL-based regimen.

Rationale: The study specifically included patients who were treated with an InSTI-based regimen and failed. The patients with virologic failure were on a RAL-based regimen, meaning they were receiving an InSTI at the time of failure. The paper does not state that these patients were InSTI-naive before starting this regimen. In fact, for three patients, RAL was used as salvage therapy after failing a previous regimen, but the previous regimen was NNRTI-based, not InSTI-based. The paper does not provide information on the InSTI-naive status for all 258 individuals.

Answer: NA
"""

"""
Question: 4403

Evidence: Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients. Patients "1" through "3" were on NNRTI-based regimen before starting RAL-based regimen as salvage therapy.

Rationale: The paper provides details for the seven patients with virologic failure. Three of them received RAL as a second-line (salvage) therapy, meaning they had received more than one ART regimen. The other four received RAL as first-line therapy. The paper does not provide this level of detail for the entire cohort of 258 patients.

Answer: NA
"""

"""
Question: 4404

Evidence: Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients. Patients "1" through "3" were on NNRTI-based regimen before starting RAL-based regimen as salvage therapy.

Rationale: The paper details that three patients received a second regimen (RAL-based salvage). It does not mention any patient receiving a third or subsequent regimen. This information is only provided for the seven patients with failure, not the entire study population.

Answer: NA
"""

"""
Question: 4405

Evidence: Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients.

Rationale: The data for the seven patients with virologic failure shows that they did not all receive the same number of ART regimens (four were on first-line, three were on second-line). The paper does not state that this was the case for all 258 individuals in the study.

Answer: No
"""

"""
Question: 4406

Evidence: Raltegravir based-regimen was offered as first-line therapy for four patients, and as salvage therapy for three patients.

Rationale: Among the seven patients with virologic failure, three received more than one ART regimen (salvage therapy). Therefore, not all individuals in this subgroup received only one ART regimen. The paper does not provide this information for the entire study cohort.

Answer: No
"""

"""
Question: 4501

Evidence: Viral suppression was achieved in all patients on EVG-based regimen (Stribild or Genvoya), or DTG-based regimen (Tivicay + Descovy or Truvada or Epzicom).

Rationale: The paper states that all patients on DTG-based regimens achieved viral suppression. It does not provide the exact number of individuals who received dolutegravir, only that there were no failures in this group.

Answer: NA
"""

"""
Question: 4502

Evidence: The InSTI-based regimen generally consists of one InSTI plus two nucleoside reverse transcriptase inhibitors (NRTIs).

Rationale: The paper describes regimens based on InSTIs (RAL, EVG, DTG) and NRTIs. There is no mention of the protease inhibitor darunavir or any other PI being used by any patient in the study.

Answer: 0
"""

"""
Question: 5101

Evidence: Virologic failure was observed in seven patients on raltegravir-based regimen. M184V mutation associated with high level resistance to lamivudine and emtricitabine was detected in six out of seven patients. Primary mutations (Y143C, N155H, T66I, G118R, E138K) conferring high level resistance to raltegravir were detected in only three patients.

Rationale: The paper focuses on the seven patients with virologic failure. Among these seven, six had at least one drug resistance mutation (M184V and/or InSTI mutations). However, the paper does not provide a comprehensive count of individuals with resistance mutations from the entire cohort of 258 patients; it only details the failures.

Answer: NA
"""

"""
Question: 5102

Evidence: Primary mutations (Y143C, N155H, T66I, G118R, E138K) conferring high level resistance to raltegravir were detected in only three patients.

Rationale: The paper explicitly states that three of the seven patients with virologic failure had primary InSTI-resistance mutations.

Answer: 3
"""

"""
Question: 5103

Evidence: M184V mutation associated with high level resistance to lamivudine and emtricitabine was detected in six out of seven patients.

Rationale: The paper reports resistance mutations for the NRTIs lamivudine (3TC) and emtricitabine (FTC) via the M184V mutation. It does not mention any mutations specifically associated with high-level resistance to tenofovir disoproxil fumarate (TDF), such as K65R or multiple thymidine analog mutations (TAMs).

Answer: 0
"""

"""
Question: 5104

Evidence: Primary mutations (Y143C, N155H, T66I, G118R, E138K) conferring high level resistance to raltegravir were detected in only three patients. G118R, Y143C, and N155H were the major integrase mutations accounting for the virologic failure detected in three out of seven patients.

Rationale: The paper lists the specific primary InSTI-resistance mutations that were detected in the patients: Y143C, N155H, T66I, G118R, and E138K.

Answer: Y143C, N155H, T66I, G118R, E138K
"""

"""
Question: 6101

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper describes the use of genotypic resistance testing (sequencing and interpretation algorithms). It does not mention performing any phenotypic susceptibility tests, which measure viral growth in the presence of drugs in vitro.

Answer: NA
"""

"""
Question: 6102

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper does not report any IC50 or IC90 values, which are standard outputs of phenotypic susceptibility assays. The resistance assessment is purely genotypic.

Answer: No
"""

"""
Question: 6103

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper does not report any fold-change values, which are a key metric in phenotypic susceptibility testing. The analysis is based on sequence interpretation, not direct drug susceptibility measurements.

Answer: No
"""

"""
Question: 6104

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper does not describe the use of any phenotypic susceptibility assay, as the resistance testing was performed genotypically (via sequencing).

Answer: NA
"""

"""
Question: 6105

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: The paper does not mention or report any data related to the replication capacity of the HIV isolates.

Answer: No
"""

"""
Question: 6106

Evidence: The identification of HIV-1 subtype and mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors and InSTIs, was done using the Stanford University genotypic resistance interpretation algorithm.

Rationale: Since no phenotypic susceptibility testing was performed, no drugs were tested using this method.

Answer: NA
"""

"""
Question: 7101

Evidence: Blood samples were received from 258 patients with HIV-1 infection. Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks.

Rationale: The paper describes a study of viruses isolated from patients in a clinical setting. There is no mention of generating or studying any viruses with site-directed mutations, which are engineered in the laboratory.

Answer: No
"""

"""
Question: 7102

Evidence: Patients infected with HIV-1 and treated with InSTI-based regimen were followed up for 48 weeks. There were all recruited from Infectious Disease Hospital, Ministry of Health, Kuwait.

Rationale: The paper describes a clinical study involving patient samples. It does not mention any in vitro passage experiments, which involve serially passaging virus in cell culture, often under selective drug pressure.

Answer: No
"""